Literature DB >> 7476963

Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements.

H Keller1, F Givel, M Perroud, W Wahli.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) and retinoid X receptors (RXRs) are nuclear hormone receptors that are activated by fatty acids and 9-cis-retinoic acid, respectively. PPARs and RXRs form heterodimers that activate transcription by binding to PPAR response elements (PPREs) in the promoter of target genes. The PPREs described thus far consist of a direct tandem repeat of the AGGTCA core element with one intervening nucleotide. We show here that the vitellogenin A2 estrogen response element (ERE) can also function as a PPRE and is bound by a PPAR/RXR heterodimer. Although this heterodimer can bind to several other ERE-related palindromic response elements containing AGGTCA half-sites, only the ERE is able to confer transactivation of test reporter plasmids, when the ERE is placed either close to or at a distance from the transcription initiation site. Examination of natural ERE-containing promoters, including the pS2, very-low-density apolipoprotein II and vitellogenin A2 genes, revealed considerable differences in the binding of PPAR/RXR heterodimers to these EREs. In their natural promoter context, these EREs did not allow transcriptional activation by PPARs/RXRs. Analysis of this lack of stimulation of the vitellogenin A2 promoter demonstrated that PPARs/RXRs bind to the ERE but cannot transactivate due to a nonpermissive promoter structure. As a consequence, PPARs/RXRs inhibit transactivation by the estrogen receptor through competition for ERE binding. This is the first example of signaling cross-talk between PPAR/RXR and estrogen receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7476963     DOI: 10.1210/mend.9.7.7476963

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  53 in total

1.  Inhibition of retinol oxidation by ethanol in the rat liver and colon.

Authors:  A Parlesak; I Menzl; A Feuchter; J C Bode; C Bode
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  Effect of polymorphism in the peroxisome proliferator-activated receptor gamma gene on litter size of pigs.

Authors:  Guiying Wang; Lujun Kong; Peng Hu; Jinlian Fu; Aiguo Wang
Journal:  Mol Biol Rep       Date:  2010-09-29       Impact factor: 2.316

3.  Is there an estrogenic component in the metabolic syndrome?

Authors:  S Starcke; G Vollmer
Journal:  Genes Nutr       Date:  2006-09       Impact factor: 5.523

4.  Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice.

Authors:  Nicolas Leuenberger; Sylvain Pradervand; Walter Wahli
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

5.  Intracellular receptor regulation of adipose metabolism by the isoflavone genistein.

Authors:  Isabella Zanella; Diego Di Lorenzo
Journal:  Eur J Nutr       Date:  2015-04       Impact factor: 5.614

6.  Associations of Perfluoroalkyl Substances with Incident Natural Menopause: The Study of Women's Health Across the Nation.

Authors:  Ning Ding; Siobán D Harlow; John F Randolph; Antonia M Calafat; Bhramar Mukherjee; Stuart Batterman; Ellen B Gold; Sung Kyun Park
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

7.  Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Authors:  Yuzhi Yin; Hongyan Yuan; Xiao Zeng; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Estrogen receptor-dependent genomic expression profiles in breast cancer cells in response to fatty acids.

Authors:  Faizeh Alquobaili; Stacy-Ann Miller; Seid Muhie; Agnes Day; Marti Jett; Rasha Hammamieh
Journal:  J Carcinog       Date:  2010-02-04

9.  PPARα in Obesity: Sex Difference and Estrogen Involvement.

Authors:  Michung Yoon
Journal:  PPAR Res       Date:  2010-08-17       Impact factor: 4.964

10.  Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).

Authors:  Carmen Aceves; Pablo García-Solís; Omar Arroyo-Helguera; Laura Vega-Riveroll; Guadalupe Delgado; Brenda Anguiano
Journal:  Mol Cancer       Date:  2009-06-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.